Reuters logo
BRIEF-Abeona says ABO-102 well-tolerated in six subjects through 1100 days follow up
2017年5月12日 / 中午12点14分 / 6 个月前

BRIEF-Abeona says ABO-102 well-tolerated in six subjects through 1100 days follow up

May 12 (Reuters) - Abeona Therapeutics Inc

* Abeona therapeutics announces top-line data for abo-102 phase 1/2 mps iiia gene therapy trial at asgct

* Abeona therapeutics inc - abo-102 well-tolerated in six subjects through 1100 days follow up with no serious adverse events

* Abeona therapeutics inc- abo-102 well-tolerated in six subjects through 1100 days follow up with no serious adverse events

* Abeona - positive dose response in central nervous system with 60.7% +/- 8.8% reduction of disease-causing heparan sulfate gag observed in cohort 2

* Abeona therapeutics inc - reduction of disease manifestation observed in decreased liver volume of 14.81% (+/- 1.2%)

* Abeona therapeutics inc - cohort 1 demonstrated stabilized or improved leiter nonverbal iq scores at six months Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below